FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016751107> ?p ?o ?g. }

• W2016751107 endingPage "2055" @default.
• W2016751107 startingPage "2055" @default.
• W2016751107 abstract "<h3>Objective.</h3> —To assess the efficacy and cost-effectiveness of standard chemotherapy and high-dose chemotherapy with autologous bone marrow transplantation (ABMT) in metastatic breast cancer. <h3>Design.</h3> —Decision analysis model using a Markov process. <h3>Setting.</h3> —Response and recurrence rates from the published literature for standard therapy and from case series of ABMT. Costs were based on local charges and on adjusted Medicare data. <h3>Patients.</h3> —Hypothetical cohorts of women with metastatic breast cancer who had no bone marrow involvement and no comorbid illness. <h3>Intervention.</h3> —The standard chemotherapy cohort received cyclophosphamide, doxorubicin, and fluorouracil. The ABMT cohort was treated with intense induction chemotherapy, then additional high-dose chemotherapy following a remission, with ABMT support. <h3>Main Outcome Measures.</h3> —Anticipated survival, incremental cost per year of life, and incremental cost per quality-adjusted year of life gained using a 5-year time horizon. Rigorous sensitivity analyses were done, including assessing a benefit tail of normal life expectancy for those free of disease after 5 years. <h3>Results.</h3> —ABMT was the preferred approach under almost all assumptions, but the size of the benefit varied greatly. ABMT had a survival benefit of 6.0 months at 5 years at an incremental cost of $115 800 per year of life saved. If patients who were free of disease after 5 years had normal survival, the benefit was 18.1 months at an incremental cost of $28 600 per year. The benefit of ABMT was primarily dependent on whether the recurrence risk was constant or decreases after a finite period of time. <h3>Conclusion.</h3> —Using reasonable assumptions, ABMT provided a substantial benefit but at a cost that may be untenable. Decision analysis highlights the limitations in the currently available data and the assumptions made for the emotional question of using ABMT in metastatic breast cancer. The model supports the need for randomized clinical trials. (<i>JAMA</i>. 1992;267:2055-2061)" @default.
• W2016751107 created "2016-06-24" @default.
• W2016751107 creator A5003643842 @default.
• W2016751107 creator A5029509004 @default.
• W2016751107 creator A5081792160 @default.
• W2016751107 date "1992-04-15" @default.
• W2016751107 modified "2023-09-23" @default.
• W2016751107 title "Efficacy and Cost-effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast Cancer" @default.
• W2016751107 cites W135617309 @default.
• W2016751107 cites W1566936261 @default.
• W2016751107 cites W1785581158 @default.
• W2016751107 cites W1843893004 @default.
• W2016751107 cites W1929549982 @default.
• W2016751107 cites W1933724083 @default.
• W2016751107 cites W1938930090 @default.
• W2016751107 cites W1985609148 @default.
• W2016751107 cites W1987684534 @default.
• W2016751107 cites W1988822590 @default.
• W2016751107 cites W1995627591 @default.
• W2016751107 cites W2034294525 @default.
• W2016751107 cites W2035382227 @default.
• W2016751107 cites W2052124973 @default.
• W2016751107 cites W2052984045 @default.
• W2016751107 cites W2061455688 @default.
• W2016751107 cites W2078241672 @default.
• W2016751107 cites W2083224152 @default.
• W2016751107 cites W2085608459 @default.
• W2016751107 cites W2088067517 @default.
• W2016751107 cites W2089405761 @default.
• W2016751107 cites W2090011060 @default.
• W2016751107 cites W2126281686 @default.
• W2016751107 cites W2149015752 @default.
• W2016751107 cites W2165763581 @default.
• W2016751107 cites W2220500259 @default.
• W2016751107 cites W2270879120 @default.
• W2016751107 cites W2272365488 @default.
• W2016751107 cites W2276085691 @default.
• W2016751107 cites W2473387326 @default.
• W2016751107 cites W2593892363 @default.
• W2016751107 cites W2771456724 @default.
• W2016751107 cites W8593122 @default.
• W2016751107 cites W2416188809 @default.
• W2016751107 doi "https://doi.org/10.1001/jama.1992.03480150061038" @default.
• W2016751107 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1552641" @default.
• W2016751107 hasPublicationYear "1992" @default.
• W2016751107 type Work @default.
• W2016751107 sameAs 2016751107 @default.
• W2016751107 citedByCount "120" @default.
• W2016751107 countsByYear W20167511072012 @default.
• W2016751107 countsByYear W20167511072013 @default.
• W2016751107 countsByYear W20167511072015 @default.
• W2016751107 countsByYear W20167511072016 @default.
• W2016751107 countsByYear W20167511072018 @default.
• W2016751107 crossrefType "journal-article" @default.
• W2016751107 hasAuthorship W2016751107A5003643842 @default.
• W2016751107 hasAuthorship W2016751107A5029509004 @default.
• W2016751107 hasAuthorship W2016751107A5081792160 @default.
• W2016751107 hasConcept C112930515 @default.
• W2016751107 hasConcept C121608353 @default.
• W2016751107 hasConcept C126322002 @default.
• W2016751107 hasConcept C133925201 @default.
• W2016751107 hasConcept C141071460 @default.
• W2016751107 hasConcept C143998085 @default.
• W2016751107 hasConcept C159110408 @default.
• W2016751107 hasConcept C2775930923 @default.
• W2016751107 hasConcept C2776694085 @default.
• W2016751107 hasConcept C2776755627 @default.
• W2016751107 hasConcept C2779951463 @default.
• W2016751107 hasConcept C2908647359 @default.
• W2016751107 hasConcept C3019080777 @default.
• W2016751107 hasConcept C530470458 @default.
• W2016751107 hasConcept C64332521 @default.
• W2016751107 hasConcept C71924100 @default.
• W2016751107 hasConcept C72563966 @default.
• W2016751107 hasConcept C99454951 @default.
• W2016751107 hasConceptScore W2016751107C112930515 @default.
• W2016751107 hasConceptScore W2016751107C121608353 @default.
• W2016751107 hasConceptScore W2016751107C126322002 @default.
• W2016751107 hasConceptScore W2016751107C133925201 @default.
• W2016751107 hasConceptScore W2016751107C141071460 @default.
• W2016751107 hasConceptScore W2016751107C143998085 @default.
• W2016751107 hasConceptScore W2016751107C159110408 @default.
• W2016751107 hasConceptScore W2016751107C2775930923 @default.
• W2016751107 hasConceptScore W2016751107C2776694085 @default.
• W2016751107 hasConceptScore W2016751107C2776755627 @default.
• W2016751107 hasConceptScore W2016751107C2779951463 @default.
• W2016751107 hasConceptScore W2016751107C2908647359 @default.
• W2016751107 hasConceptScore W2016751107C3019080777 @default.
• W2016751107 hasConceptScore W2016751107C530470458 @default.
• W2016751107 hasConceptScore W2016751107C64332521 @default.
• W2016751107 hasConceptScore W2016751107C71924100 @default.
• W2016751107 hasConceptScore W2016751107C72563966 @default.
• W2016751107 hasConceptScore W2016751107C99454951 @default.
• W2016751107 hasIssue "15" @default.
• W2016751107 hasLocation W20167511071 @default.
• W2016751107 hasLocation W20167511072 @default.
• W2016751107 hasOpenAccess W2016751107 @default.
• W2016751107 hasPrimaryLocation W20167511071 @default.

• next